טוען...
Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
OBJECTIVE: The aim was to determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active psoriatic arthritis (PsA) who are tumour necrosis factor inhibitor (TNFi) naïve and without concomitant moderate-to-severe psoriasis, and who have resp...
שמור ב:
| הוצא לאור ב: | Pharmacoeconomics |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer International Publishing
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5999172/ https://ncbi.nlm.nih.gov/pubmed/29797187 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-018-0674-x |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|